AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Method for treatment of drug-resistant HIV-1

Detailed Technology Description: None

*Abstract: BackgroundNucleoside and nucleotide analog reverse transcriptase inhibitors (NRTI) are integral components of therapies for HIV-1 infection. The currently approved NRTI have significant limitations, however, that include short- and long-term toxicity, pharmacokinetic interactions with or antiretroviral drugs, and the selection of drug-resistant HIV-1 variants that are cross-resistant with other NRTI. Accordingly, there is a critical need to develop new NRTI that have excellent activity and safety profiles and exhibit little or no cross-resistance with existing drugs. TechnologyUsing data derived from such structure-activity-resistance studies, investigators at Pitt have identified a lead class of compounds that retain potent activity against many drug-resistant variants of HIV-1. These nucleoside analogs could fulfill the expanding need for NRTI that are active against drug-resistant HIV-1.Applications:1) Treatment of HIV-1 infection2) Treatment of drug-resistant HIV-1Advantages:1) Active against several drug resistant strains of HIV-1 which include HIV-1 with the drug-resistance mutations K65R, L74V or M184V 2) Active against all strains of HIV-1 that are resistant to AZTNon Provisional and PCT patent applications filed

*Principal Investigator: Name: John Mellors, Professor
Department: Med-Medicine

Name: Nicolas Sluis-Cremer, Assistant Professor
Department: Med-Medicine

Country/Region: USA

For more information, please click Here